Elizabeth Rozek's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 138,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 6, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Sagimet Biosciences Inc - ... | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 138,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
Sagimet Biosciences Inc - ... | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 34,000 | 194,506 | - | 0 | Series A Common Stock | |
Sagimet Biosciences Inc - ... | Elizabeth Rozek | General Counsel and CCO | Sale of securities on an exchange or to another person at price $ 3.10 per share. | 19 Jul 2024 | 10,914 | 160,506 | - | 3.1 | 33,830 | Series A Common Stock |
Sagimet Biosciences Inc - ... | Elizabeth Rozek | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 242,142 | - | - | Stock Option (Right to Buy) | |
Sagimet Biosciences Inc - ... | Elizabeth Rozek | General Counsel and CCO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 242,142 | 0 | - | - | Stock Option (Right to Buy) |